K

Knotus Co Ltd
KOSDAQ:278650

Watchlist Manager
Knotus Co Ltd
KOSDAQ:278650
Watchlist
Price: 2 160 KRW Market Closed
Market Cap: 181.9B KRW
Have any thoughts about
Knotus Co Ltd?
Write Note

Knotus Co Ltd
Common Shares Outstanding

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Knotus Co Ltd
Common Shares Outstanding Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Shares Outstanding CAGR 3Y CAGR 5Y CAGR 10Y
K
Knotus Co Ltd
KOSDAQ:278650
Common Shares Outstanding
â‚©78.1m
CAGR 3-Years
114%
CAGR 5-Years
67%
CAGR 10-Years
N/A
Samsung Biologics Co Ltd
KRX:207940
Common Shares Outstanding
â‚©71.2m
CAGR 3-Years
2%
CAGR 5-Years
2%
CAGR 10-Years
N/A
S
ST Pharm Co Ltd
KOSDAQ:237690
Common Shares Outstanding
â‚©18.8m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
N/A
F
FutureChem Co Ltd
KOSDAQ:220100
Common Shares Outstanding
â‚©22.1m
CAGR 3-Years
5%
CAGR 5-Years
23%
CAGR 10-Years
N/A
L
LegoChem Biosciences Inc
KOSDAQ:141080
Common Shares Outstanding
â‚©28m
CAGR 3-Years
5%
CAGR 5-Years
6%
CAGR 10-Years
7%
C
Cellivery Therapeutics Inc
KOSDAQ:268600
Common Shares Outstanding
â‚©36.7m
CAGR 3-Years
3%
CAGR 5-Years
18%
CAGR 10-Years
N/A
No Stocks Found

Knotus Co Ltd
Glance View

Market Cap
181.9B KRW
Industry
Life Sciences Tools & Services

KNOTUS Co. Ltd. engages in the provision of clinical research services. The company is headquartered in Incheon, Incheon. The company went IPO on 2019-11-27. is a Korea-based company principally engaged in the nonclinical experiment business. Along with subsidiaries, the Company operates its business through three segments. The Nonclinical Contract Research Organization (CRO) Business segment conducts nonclinical experiments on new developed substances such as new drugs, and tests the efficacy and pharmacodynamics of the substances. This segment also provides services including new drug development related equipment, software and analysis of experimental results. The Animal Laboratory Construction Business segment is engaged in the construction and design of animal laboratories and the supply of reagent consumables. The Pet Business segment is engaged in the development of animal medicines and the sale of pet supplies.

Intrinsic Value
2 258.02 KRW
Undervaluation 4%
Intrinsic Value
Price
K

See Also

What is Knotus Co Ltd's Common Shares Outstanding?
Common Shares Outstanding
78.1m KRW

Based on the financial report for Dec 31, 2023, Knotus Co Ltd's Common Shares Outstanding amounts to 78.1m KRW.

What is Knotus Co Ltd's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 5Y
67%

Over the last year, the Common Shares Outstanding growth was 11%. The average annual Common Shares Outstanding growth rates for Knotus Co Ltd have been 114% over the past three years , 67% over the past five years .

Back to Top